Table 3 Cox proportional hazard regression analysis of factors associated with Infliximab durability in patients with crohn’s disease.

From: Comparison of endoscopic healing and durability between combination therapy with infliximab and azathioprine versus infliximab monotherapy in pediatric Crohn’s disease

 

Univariate Cox analysis

Multivariate analysis (n = 108)

HR

95% CI

p

HR

95% CI

p

Sex (female vs. male)

0.62

0.39–1.66

0.963

   

Age at diagnosis

0.95

0.85–1.06

0.366

   

Disease duration at IFX initiation, years

0.73

0.10–1.77

0.723

   

Any colonic involvement

1.66

0.25–14.48

0.528

   

Any upper gastrointestinal involvement

2.713

0.98–2.55

0.522

   

Disease behavior (B1 vs. B2, B3)

1.67

0.53–3.88

0.342

   

PCDAI at diagnosis

1.00

0.97–1.03

0.897

   

ESR at diagnosis

1.00

0.99–1.01

0.393

   

Albumin at diagnosis

1.03

0.53–1.98

0.941

   

CRP at diagnosis

1.03

0.97–1.19

0.157

   

SES-CD at diagnosis

1.03

0.92–1.16

0.566

   

IFX trough concentration at 1 year

0.93

0.81–1.06

0.253

   

ATI positivity

2.64

1.26–5.53

0.010

5.33

1.61–17.60

0.006

IFX combination therapy vs. monotherapy

0.386

0.18–0.82

0.014

0.13

0.03–0.51

0.004

  1. IFX infliximab, PCDAI pediatric Crohn’s disease activity index, ESR erythrocyte sedimentation rate, CRP C-reactive protein, SES-CD simple endoscopic score for Crohn’s disease, ATI antibody to infliximab.
Back to article page